세계의 경피 패치 시장(2024-2028년)

The transdermal patches market is forecasted to grow by USD 2.00 bn during 2023-2028, accelerating at a CAGR of 5.65% during the forecast period. The report on the transdermal patches market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing demand for non-invasive drug delivery methods, increasing prevalence of chronic diseases, and rising healthcare expenditure owing to increasing investment in transdermal patch development.

Technavio's transdermal patches market is segmented as below:

By Application

• Pain management
• Central nervous system disorders
• Hormonal application
• Cardiovascular diseases
• Others

By End-user

• Homecare
• Hospitals and clinics

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development of microneedle patches for enhanced drug delivery efficiency as one of the prime reasons driving the transdermal patches market growth during the next few years. Also, the expansion of transdermal patch applications into dermatological and cosmetic fields and the adoption of sustainable and biodegradable materials in patch manufacturing will lead to sizable demand in the market.

The report on the transdermal patches market covers the following areas:

• Transdermal patches market sizing
• Transdermal patches market forecast
• Transdermal patches market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading transdermal patches market vendors that include Alvogen Iceland ehf, Boehringer Ingelheim International GmbH, Endo International Plc, Hisamitsu Pharmaceutical Co. Inc., IontoPatch, Johnson and Johnson Services Inc., Lead Chemical Co. Ltd., Luye Pharma Group Ltd., Medherant Ltd., Mundipharma International Ltd., Nitto Denko Corp., Novartis AG, Purdue Pharma LP, Sparsha Pharma International Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., AdhexPharma SAS, Agile Therapeutics Inc., Bayer AG, and Evernow Inc. Also, the transdermal patches market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global transdermal patches market 2018 - 2022
• 4.2 Application Segment Analysis 2018 - 2022
• 4.3 End User Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Application

• 6.1 Market segments
• 6.2 Comparison by Application
• 6.3 Pain management - Market size and forecast 2023-2028
• 6.4 Central nervous system disorders - Market size and forecast 2023-2028
• 6.5 Hormonal application - Market size and forecast 2023-2028
• 6.6 Cardiovascular diseases - Market size and forecast 2023-2028
• 6.7 Others - Market size and forecast 2023-2028
• 6.8 Market opportunity by Application

7 Market Segmentation by End-user

• 7.1 Market segments
• 7.2 Comparison by End-user
• 7.3 Homecare - Market size and forecast 2023-2028
• 7.4 Hospitals and clinics - Market size and forecast 2023-2028
• 7.5 Market opportunity by End-user

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 UK - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity by geography

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Agile Therapeutics Inc.
• 12.4 Alvogen Iceland ehf
• 12.5 Bayer AG
• 12.6 Boehringer Ingelheim International GmbH
• 12.7 Endo International Plc
• 12.8 Hisamitsu Pharmaceutical Co. Inc.
• 12.9 IontoPatch
• 12.10 Johnson and Johnson Services Inc.
• 12.11 Lead Chemical Co. Ltd.
• 12.12 Luye Pharma Group Ltd.
• 12.13 Nitto Denko Corp.
• 12.14 Novartis AG
• 12.15 Purdue Pharma LP
• 12.16 Teva Pharmaceutical Industries Ltd.
• 12.17 Viatris Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations